Novel diagnostic improvements and therapy candidates continue to surface. Apellis Pharmaceuticals gained FDA approval expanding Empaveli's use to two rare kidney diseases, complement 3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. Meanwhile, a multiplexed tool for gene and cell doping detection utilizing CRISPR-Cas was developed, supporting ethics in sports. Additionally, new AI-driven chromatographic monitoring boosts monoclonal antibody manufacturing yields. Research groups unveiled a novel plasma synuclein test offering enhanced Parkinson’s diagnosis. Gene-edited prime editing showed promise for rare childhood hemiplegia disorder treatment in mouse models.